Q71: Neurology: PLAB/UK(MLA)/AKT Exam style question
Today we will discuss another Q71 Neurology PLAB 1/ UKMLA exam question. This is a common topic that has appeared in the past PLAB 1 exam.
A 61-year-old woman presents to the emergency department with morning headaches, nausea, and vomiting. An urgent CT head reveals a mass within the right frontal lobe, and a subsequent MRI head confirms a glioblastoma surrounded by edema. The patient is started on dexamethasone for the cerebral edema. Which of the following is a potential side effect of dexamethasone therapy in this patient?
A. Hypoglycemia
B. Bradycardia
C. Hyperkalemia
D. Immunosuppression
E. Hyponatremia
Answer is given below
Past PLAB 1 candidates reviews about MedRevisions with results
Follow us on telegram for more free questions
PLAB or MLA exam Study groups: Find the 10% discount referral links here
Articles with important insight:
Important update to the PLAB exam: Is the PLAB exam based on the MLA content map from August 2024 onward? Find out more about the change and how to prepare for it here.
Evolving Nature of PLAB 1 Exam Questions: Is the exam getting tougher? A Closer Look with examples
What Past PLAB 1 candidates say about us (with exam results)
The correct answer is D
Explanation
Dexamethasone is a potent glucocorticoid steroid used to treat vasogenic edema that occurs due to the breakdown of the blood-brain barrier, as is commonly seen in patients with brain tumors. Its use is essential in managing cerebral edema in patients with glioblastoma.
However, dexamethasone therapy is associated with several side effects, one of which is immunosuppression (option D). Glucocorticoids, such as dexamethasone, can suppress the immune response, making patients more susceptible to infections. This effect is especially relevant for patients undergoing surgery or other invasive procedures, as well as those receiving concomitant immunosuppressive treatments, such as chemotherapy.
Hypoglycemia (option A) is not a typical side effect of dexamethasone therapy; in fact, glucocorticoids may cause hyperglycemia by increasing gluconeogenesis and insulin resistance.
Bradycardia (option B) is not typically associated with dexamethasone use. Glucocorticoids can cause fluid retention and hypertension but do not directly affect heart rate.
Hyperkalemia (option C) is not a side effect of dexamethasone therapy. Glucocorticoids can cause hypokalemia due to their mineralocorticoid effects, promoting potassium excretion in the kidneys.
Hyponatremia (option E) is not a typical side effect of dexamethasone. Glucocorticoids can cause fluid retention, which may lead to dilutional hyponatremia in some cases, but this is not a direct effect of the drug on sodium levels.
Other answer options are heavily discussed in our platform, sign up for our PLAB or UKMLA services and get access to all the necessary materials required to pass the exam.
The above question is a high-yield exam PLAB 1 / UKMLA question-style question. At MedRevisions, We provide questions and not only explain the correct answer, we also explain the wrong answer so you will have a comprehensive understanding of the concepts that is commonly tested in the exam. On top of that, we also provide you PLAB 1 / UKMLA exam curated notes with no additional cost.
To discuss to more PLAB or UK-MLA exam questions, Join: PLAB 1 /UKMLA exam study group
At MedRevisions, we strive hard to provide the most up-to-date content available for PLAB Part 1. We constantly add exam-style questions derived from the most recent exam and also update the content to align with the latest NICE/CKS guidelines to ensure doctors pass PLAB Part 1 or UKMLA exam with ease in ONE attempt.
Past PLAB 1 candidates reviews about MedRevisions
How to use MedRevisions effectively for the PLAB 1 exam/ UKMLA exam preparation
Previous PLAB 1 or UKMLA exam guideline update
All MedRevisions recent updates
Check out this cardiology PLAB 1 exam style question
What we provide:
✅ 4600+ PLAB / UKMLA exam-style questions
✅ Perfectly tailored PLAB / UKMLA exam style notes
✅ 26 exam PLAB / UKMLA exam mocks
✅ Spaced repetition learning tool
Reference:
Dexamethasone intravitreal implant for treating diabetic macular oedema | NICE: This is a final draft guidance from NICE that recommends dexamethasone intravitreal implant for treating visual impairment due to diabetic macular edema only if the diabetic macular edema has not responded well enough to non-corticosteroids, or non-corticosteroids are unsuitable. It also specifies the criteria for starting and stopping treatment, and the need for regular monitoring of intraocular pressure and cataract progression. It was published in March 2021.
Dexamethasone and cerebral edema | Alberta Health Services: This is a document from the Alberta Health Services that provides recommendations on the use of dexamethasone in patients with high-grade gliomas and cerebral edema. It covers the indications, dosage, duration, monitoring, and adverse effects of dexamethasone therapy. It was last updated in February 2021.
Hyperosmolar Therapy for Acute Cerebral Edema | Neurocritical Care Society: This is a guideline from the Neurocritical Care Society that evaluates the role of hyperosmolar agents (mannitol, HTS), corticosteroids, and selected non-pharmacologic therapies in the acute treatment of cerebral edema. It provides recommendations regarding initial management of cerebral edema in neurocritical care patients with subarachnoid hemorrhage, traumatic brain injury, acute ischemic stroke, intracerebral hemorrhage, bacterial meningitis, and hepatic encephalopathy. It was published in January 2016.